Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01650285
Recruitment Status : Terminated
First Posted : July 26, 2012
Results First Posted : June 29, 2015
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
Dr Anthony Mega, Brown University

Tracking Information
First Submitted Date  ICMJE July 24, 2012
First Posted Date  ICMJE July 26, 2012
Results First Submitted Date  ICMJE July 14, 2014
Results First Posted Date  ICMJE June 29, 2015
Last Update Posted Date July 17, 2018
Study Start Date  ICMJE January 2013
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 9, 2015)
Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation [ Time Frame: 2 mos ]
The MTD was not determined secondary to the study closing early. That being said the numbers provided below show that 4 patients were treated on study to aide in the investigation of the MTD. Only 1 dose was fully evaluated which was 5mg/m2
Original Primary Outcome Measures  ICMJE
 (submitted: July 24, 2012)
To determine the maximum tolerated dose of cabazitaxel with concurrent adjuvant radiation [ Time Frame: 2 mos ]
Change History Complete list of historical versions of study NCT01650285 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 20, 2018)
Number of Participants Experiencing a Toxicity Associated With Cabazitaxel and Adjuvant Radiation Following Prostatectomy for Patients With Stage 3 Prostate Cancer and for Patients With a PSA Elevation Post-Prostatectomy. [ Time Frame: During study treatment (approximately 8 weeks) through 30 days post treatment, approximately 12 weeks. ]
Assess toxicity using CTCAE version 4.0. Number of patients who experienced a toxicity on the study. Not all toxicities are related to study treatment. Of note, there were no serious adverse events on this trial.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2012)
To assess the toxicity associated with cabazitaxel and adjuvant radiation [ Time Frame: 2 mos ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: July 24, 2012)
To determine the time to progression and overall survival for patients-Following Radical Prostatectomy and were treated with cabazitaxal. [ Time Frame: 24 months ]
 
Descriptive Information
Brief Title  ICMJE Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL)
Official Title  ICMJE Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Following Radical Prostatectomy
Brief Summary There is a high relapse rate for patients who have undergone prostatectomy and have pathologic extracapsular prostate extension, positive surgical margins or seminal vesicle involvement (pathologic stage 3 disease). While adjuvant radiation improves progression-free and overall survival, approximately half of these patients will develop recurrence. Similarly, radiation therapy has become the standard salvage therapy for patients with rising PSA >0.1 - < 2.0 ng/mL. In common solid tumors such as NSCLC, head and neck cancer and upper gastrointestinal cancers, the addition of chemotherapy to radiation improves survival. It is hypothesized that the addition of radiosensitizing chemotherapy to standard adjuvant radiation will improve survival in patients with stage 3 prostate cancer after prostatectomy and patients with rising PSA < 2.0 ng.mL without detectable disease. Taxanes are powerful radiation enhancers since they synchronize tumor cells in G2/M the most radiosensitive phase of the cell cycle.17,18 Cabazitaxel is the most active taxane in the treatment of prostate cancer. Therefore, we propose a phase I study establishing the optimal dose of cabazitaxel with adjuvant radiation for stage 3 prostate cancer after prostatectomy (PSA undetectable - < 2.0 ng/mL). and for patients with persistent or rising PSA post prostatectomy (PSA >0.1 - < 2.0 ng/mL).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE Drug: Cabazitaxel

Dose Level Day 1, 22, 43

  1. 5.0 mg/m2
  2. 10.0 mg/m2
  3. 15.0 mg/m2
  4. 20.0 mg/m2
Study Arms  ICMJE Experimental: Cabazitaxel and radiation
Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Intervention: Drug: Cabazitaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: June 9, 2015)
5
Original Estimated Enrollment  ICMJE
 (submitted: July 24, 2012)
24
Actual Study Completion Date  ICMJE July 2014
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Conditions for Patient Eligibility

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  • Radical prostatectomy for adenocarcinoma of the prostate with at least one of the following:

    • Extracapsular tumor extension,
    • Positive surgical margins,
    • Seminal vesicle invasion
    • Regional lymph node positive (N1)
    • Post-prostatectomy PSA of > 0.1 - < 2.0 ng/mL at least 6 weeks after prostatectomy and within 30 days of registration in a patient with T2 or T3 disease at prostatectomy.
  • No distant metastases.
  • No prior pelvic or prostate radiation or chemotherapy for prostate cancer.
  • ECOG performance status 0-1.
  • Age>18.
  • Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500 cells/mm3; platelet count ≥100,000 cells/mm3, Creatinine ≤ 1.5X upper limit of normal (if creatinine clearance 1.0-1.5x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Group formula and patients with creatinine clearance < 60 ml/min should be excluded),19 .Hgb > 9.0 g/dl, total bilirubin ≤ 1x ULN, and AST or ALT ≤ 2.5 x ULN.
  • Life expectancy of at least 1 year.
  • Must not have uncontrolled severe, intercurrent illness.
  • No concurrent anticancer therapy.
  • Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
  • Signed study-specific consent form prior to study entry.
  • Conditions for Patient Ineligibility

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Evidence of distant metastases (M1). Equivocal bone scans are allowed if plain films are negative for metastasis.
  • Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the oral cavity or bladder are permissible).
  • History of severe hypersensitivity (> grade 3) reaction to Cabazitaxel or other drugs formulated with polysorbate 80.
  • History of severe hypersensitivity (> grade 3) to docetaxel.
  • Any uncontrolled severe, intercurrent illness (including uncontrolled diabetes)
  • At least 4 weeks since any major surgery.
  • Patients on concurrent anticancer therapy.
  • PSA > 2ng/ml
  • Concurrent or planned treatment with strong inhibitors or inducers of cytochrome p450 3A4/5 (a one-week wash out period is necessary for patients who are already on these treatments (see appendix H and I)
  • Androgen deprivation therapy started prior to prostatectomy for > 6 months duration;
  • Neoadjuvant chemotherapy prior to prostatectomy;
  • Prior cryosurgery or brachytherapy of the prostate; prostatectomy should be the primary treatment and not a salvage procedure;
  • Prior pelvic radiotherapy;
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01650285
Other Study ID Numbers  ICMJE BrUOG 246
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr Anthony Mega, Brown University
Study Sponsor  ICMJE Brown University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Howard Safran, MD Brown University
Principal Investigator: anthony mega, md Lifespan
PRS Account Brown University
Verification Date June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP